X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Richard Moscicki, M.D.

Richard Moscicki, M.D. Dr. Moscicki serves as executive vice president, Science and Regulatory Advocacy and chief medical officer at PhRMA. He joined the organization in 2017 after serving as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) since 2013. While at FDA, Dr. Moscicki brought executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER’s programs. Previous positions include serving as Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs for the company. He served as the senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013.

Recent Posts

Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers

By Richard Moscicki, M.D.  |    June 4, 2021
More than 6 million Americans, most of them age 65 or older, live with Alzheimer’s disease, a devastating degenerative brain disease and the most common form of dementia. After heart disease and...   Read More

Patient safety is at the heart of COVID-19 vaccine R&D

By Richard Moscicki, M.D.  |    April 26, 2021
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is continuing working around the clock to research, develop and manufacture vaccines to prevent...   Read More

How industry collaboration and partnerships are supporting COVID-19 vaccine manufacturing

By Richard Moscicki, M.D.  |    March 4, 2021
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 vaccine manufacturing. Companies are working to source needed raw materials and other...   Read More

Fighting variants of COVID-19

By Richard Moscicki, M.D.  |    February 22, 2021
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. To date, two...   Read More

Lessons learned from COVID-19: The way we develop new medicines is changing

By Richard Moscicki, M.D.  |    February 10, 2021
The COVID-19 pandemic has affected nearly every aspect of society, including the way scientists conduct the testing of medicines.   Read More

Just released: PhRMA members’ new clinical trial diversity principles

By Richard Moscicki, M.D.  |    November 18, 2020
Yesterday, PhRMA published first ever industry-wide principles on clinical trial diversity, a new chapter in the already existing “Principles on Conduct of Clinical Trials & Communication of Clinical...   Read More

Understanding the emergency use authorization process for COVID-19 vaccines

By Richard Moscicki, M.D.  |    November 12, 2020
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop safe and effective vaccines to prevent infection, as well as...   Read More

Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot

By Richard Moscicki, M.D.  |    October 8, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, another virus with deadly consequences is right around the corner. The COVID-19 pandemic has led to more than 7.5...   Read More

How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective­

By Richard Moscicki, M.D.  |    August 28, 2020
As the world continues to feel the impact of COVID-19, the biopharmaceutical industry is working around the clock to identify and develop safe and effective vaccines to prevent infection, while also...   Read More

Clinical Trials Awareness Week: Recognizing unsung heroes in medical research

By Richard Moscicki, M.D.  |    May 18, 2020
This week is Clinical Trials Awareness Week — an event to recognize the importance of clinical trials, raise public awareness of clinical research and honor clinical research professionals and...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."